Bcl-2蛋白在肿瘤放化疗氧化损伤中的作用

doi:10.3969/j.issn.1004-616x.2014.05.009

癌变·畸变·突变

Bcl-2蛋白在肿瘤放化疗氧化损伤中的作用

秦绪军，何伟，海春旭*

第四军医大学预防医学院毒理学教研室，陕西省自由基生物学与医学重点实验室，第四军医大学抗氧化损伤防治研究中心，陕西西安 710032

收稿日期:2013-12-12 修回日期:2014-05-30 出版日期:2014-09-30 发布日期:2014-09-30
通讯作者: 海春旭，E-mail：cx-hai@fmmu.edu.cn
作者简介:秦绪军(1976- )，男，辽宁省抚顺人，博士，研究方向：线粒体活性氧与肿瘤及衰老。Tel：15291850398；E-mail：qinxujun @hotmail.com

Role of protein Bcl-2 in the oxidative injury induced by radiotherapy or chemotherapy

QIN Xu-jun，HE Wei，HAI Chun-xu*

Department of Toxicology, the Key Laboratory of Free Radical Biology and Medicine of Shaanxi Province, Center of Prevention and Treatment on Oxidative Injury, School of Preventive Medicine, Fourth Military Medical University, Xi’an 710032, Shaanxi, China

Received:2013-12-12 Revised:2014-05-30 Online:2014-09-30 Published:2014-09-30

摘要/Abstract

摘要：

目的：探讨Bcl-2蛋白在肿瘤放化疗氧化损伤中的作用。方法：采用已建立的大鼠肿瘤放、化疗模型，分别设阴性对照组、模型组、单纯放(化)疗组、以及放(化)疗+抗氧化剂保护组。放疗大鼠给予肿瘤局部累计剂量47 Gy的60Co γ射线照射。化疗大鼠每两日1次给予2 mg/kg阿霉素腹腔注射化疗，连续注射8周。抗氧化剂保护组(安体欣60 mg/kg+Vit E 20 mg/kg+单宁2.5 mg/kg) 每日给予复合抗氧化剂灌胃1次，放疗实验大鼠连续给药5周，化疗实验大鼠连续给药8周。实验结束时处死实验动物，分别取放疗靶器官肝组织和化疗靶器官心肌组织，固定切片，采用免疫组化检测Bcl-2蛋白的表达，并对阳性显色进行光密度的量化分析。结果：Bcl-2蛋白在正常对照组的相应组织中均有一定程度的表达。与对照组比较，单纯放、化疗组可以显著抑制Bcl-2蛋白在相应靶器官组织中的表达(P<0.05)，而给予抗氧化剂保护后Bcl-2蛋白的表达较相应单纯放、化疗组显著提高(P<0.05)。结论：Bcl-2是肿瘤放、化疗氧化损伤的一个重要靶分子，同时也是一个外源性抗氧化干预的重要靶点。

关键词: Bcl-2蛋白, 放疗, 化疗, 抗氧化剂, 靶点

Abstract:

OBJECTIVE: To evaluate role of protein Bcl-2 in the oxidative injury induced by radiotherapy or chemotherapy. METHODS：We employed the rat models for radiotherapy and chemotherapy. For each experiment，the rats were divided into four groups：control group，model group，radiotherapy or chemotherapy group，and protection group. The rats for radiotherapy experiment received local radiation of 60Co γ with the accumulative dosage of 47 Gy. The rats for chemotherapy experiment received doxorubicin (2 mg/kg) by intraperitoneal injection every two days. The protection groups received multiple antioxidants (Antitoxin 60 mg/kg+Vit E 20 mg/kg+Tannin 2.5 mg/kg) by gavage every day. These treatments lasted 5 weeks for radiotherapy experiment and 8 weeks for chemotherapy experiment. At the end of the experiments，all of the rats were sacrificed and the specific tissues were fixed to cut sections. The expression of protein Bcl-2 was measured by immunohistochemistry and the positive stainings were quantified by optical density analysis. RESULTS：There was a certain positive expression of protein Bcl-2 in the normal rats. Radiotherapy or chemotherapy treatment significantly inhibited the protein Bcl-2 expression (P<0.05)，in which antioxidant supplementations showed obvious protection (P<0.05). CONCLUSION：Protein Bcl-2 was a key target of oxidative injury induced by radiotherapy and chemotherapy，as well as a potential target of antioxidant supplementation to reduce the side effects of radiotherapy and chemotherapy.

Key words: Bcl-2, radiotherapy, chemotherapy, antioxidant, target

秦绪军，何伟，海春旭*. Bcl-2蛋白在肿瘤放化疗氧化损伤中的作用[J]. 癌变·畸变·突变, doi: 10.3969/j.issn.1004-616x.2014.05.009.

QIN Xu-jun，HE Wei，HAI Chun-xu*. Role of protein Bcl-2 in the oxidative injury induced by radiotherapy or chemotherapy[J]. Carcinogenesis, Teratogenesis & Mutagenesis, doi: 10.3969/j.issn.1004-616x.2014.05.009.

参考文献

[1] Khan HA，Alhomida AS. A review of the logistic role of L-carnitine in the management of radiation toxicity and radiotherapy side effects[J]. J Appl Toxicol，2011，31(8)：707-713.

[2] Carvalho C，Santos RX，Cardoso S，et al. Doxorubicin：the good，the bad and the ugly effect[J]. Curr Med Chem，2009， 16(25)：3267-3285.

[3] Azim HA Jr，de Azambuja E，Colozza M，et al. Long-term toxic effects of adjuvant chemotherapy in breast cancer[J]. Ann Oncol，2011，22(9)：1939-1947.

[4] Klopp AH，Eifel PJ. Chemoradiotherapy for cervical cancer in 2010[J]. Curr Oncol Rep，2011，13(1)：77-85.

[5] 秦绪军，海春旭，何伟，等. 复方中药抗氧化剂对局部60Co照射荷瘤大鼠肝氧化损伤的保护作用[J]. 世界华人消化杂志，2004，12(9)：2135-2139.

[6] Qin XJ，He W，Hai CX，et al. Protection of multiple antioxidants Chinese herbal medicine on the oxidative stress induced by adriamycin chemotherapy[J]. J Appl Toxicol， 2008，28(3)：271-282.

[7] Porcelli AM，Ghelli A，Iommarini L，et al. The antioxidant function of Bcl-2 preserves cytoskeletal stability of cells with defective respiratory complex I[J]. Cell Mol Life Sci，2008， 65(18)：2943-2951.

[8] Zimmermann AK，Loucks FA，Schroeder EK，et al. Glutathione binding to the Bcl-2 homology-3 domain groove：a molecular basis for Bcl-2 antioxidant function at mitochondria [J]. J Biol Chem，2007，282(40)：29296-29304.

[9] Kelly PN，Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy[J]. Cell Death Differ，2011，18(9)：1414-1424.

[10] Shamas-Din A，Kale J，Leber B，et al. Mechanisms of action of Bcl-2 family proteins[J]. Cold Spring Harb Perspect Biol， 2013，5(4)：a008714.

[11] Martinou JC，Youle RJ. Mitochondria in apoptosis：Bcl-2 family members and mitochondrial dynamics[J]. Dev Cell， 2011，21(1)：92-101.

[12] Thomas S，Quinn BA，Das SK，et al. Targeting the Bcl-2 family for cancer therapy[J]. Expert Opin Ther Targets，2013， 17(1):61-75.

[13] Hockenbery DM，Oltvai ZN，Yin XM，et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis[J]. Cell，1993， 75(2)：241-251.

[14] Handy DE，Loscalzo J. Redox regulation of mitochondrial function[J]. Antioxid Redox Signal，2012，16(11)：1323-1367.

[15] Low IC，Chen ZX，Pervaiz S. Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells[J]. Antioxid Redox Signal，2010，13(6)：807-819.

[16] Low IC，Kang J，Pervaiz S. Bcl-2：a prime regulator of mitochondrial redox metabolism in cancer cells[J]. Antioxid Redox Signal，2011，15(12)：2975-2987.

Bcl-2蛋白在肿瘤放化疗氧化损伤中的作用

Role of protein Bcl-2 in the oxidative injury induced by radiotherapy or chemotherapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于卫华, 孔德钦, 龙子, 刘瑞, 李文丽, 海春旭. 抗氧化悖论真的成立吗？[J]. 癌变·畸变·突变, 2021, 33(5): 388-392.
[2]	马亚南, 吴楠, 金焰. 肿瘤微环境与卵巢癌化疗耐药机制的研究进展[J]. 癌变·畸变·突变, 2021, 33(5): 393-395,400.
[3]	张玉铃, 吴俊东, 潘东岳, 陈春发. 乳腺癌新辅助化疗前后Ki67变化对疗效及预后的意义[J]. 癌变·畸变·突变, 2021, 33(3): 230-235,245.
[4]	焦文静, 郭秀娟, 马鸣, 邵俊国, 张金艳. 老年局部晚期食管癌同步放化疗与单纯放疗的疗效比较[J]. 癌变·畸变·突变, 2021, 33(2): 124-128.
[5]	陈秀琼, 孟凡桥, 熊华, 王雅丽, 周洋媚, 唐雯华, 邹燕梅. 胃癌相关核心基因的生物信息学分析[J]. 癌变·畸变·突变, 2019, 31(4): 308-314.
[6]	万树泉, 魏丽军, 王福花, 曾勇. miR-200b-3p和PAK2 mRNA在耐药卵巢癌组织中的表达及其临床意义[J]. 癌变·畸变·突变, 2019, 31(3): 216-221.
[7]	吴异兰, 王晗. 白藜芦醇对肺癌紫杉醇耐药细胞的增殖抑制作用及其机制[J]. 癌变·畸变·突变, 2018, 30(3): 200-203,208.
[8]	郭晓, 王蕊, 吴娟, 纪晓坤, 王珩, 张艳, 马阳, 杜芸. 肺腺癌患者新鲜细胞学标本EGFR基因突变检测及意义[J]. 癌变·畸变·突变, 2018, 30(1): 67-70.
[9]	高飞, 王英滨. 贝伐单抗动脉介入超选化疗对大鼠脑胶质瘤的影响[J]. 癌变·畸变·突变, 2018, 30(1): 62-66.
[10]	何曙芝, 赵跃, 刘洋, 杨留才, 陈平, 刘冉. 盐城地区食管癌化疗患者近期生命质量评价[J]. 癌变·畸变·突变, 2017, 29(6): 437-444,449.
[11]	杨兴肖, 马鸣, 单保恩, 李幼梅, 宋姮, 刘志坤, 祝淑钗. 华蟾素注射液对人食管癌细胞增殖、侵袭和化疗敏感性的影响及其机制[J]. 癌变·畸变·突变, 2017, 29(2): 96-101.
[12]	阿衣古丽·哈热, 陆艳荣, 伊斯刊达·阿不力米提, 张瑾熔. 直肠癌新辅助放化疗前后LGR5基因表达的变化及其与疗效的关系[J]. 癌变·畸变·突变, 2017, 29(1): 60-64,69.
[13]	游路宽, 佘亚军, 陈初鹏. 细胞周期蛋白E1与恶性肿瘤关系的研究进展[J]. 癌变·畸变·突变, 2016, 28(6): 487-490.
[14]	吴华涛, 沈家欣, 刘静. Notch3增强三阴性乳腺癌MDA-MB-231细胞对顺铂的敏感性[J]. 癌变·畸变·突变, 2016, 28(2): 111-114,120.
[15]	熊术道, 王会平, 蒲连芳, 胡林辉, 张翠, 杨冬冬, 翟志敏. 儿童急性B淋巴细胞白血病缓解期外周血MDSCs的变化及意义[J]. 癌变·畸变·突变, 2015, 27(6): 454-458.